Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-1-8
pubmed:abstractText
The effects of the muscarinic agonist carbachol, histamine and bradykinin on incorporation of [3H]inositol into the phosphoinositides and the formation of [3H]InsPs were examined in bovine tracheal smooth-muscle (BTSM) slices labelled with [3H]inositol. These agonists result in substantial and dose-related increases in the incorporation of [3H]inositol into the phospholipids. Carbachol and histamine stimulated the incorporation of [3H]inositol into the phospholipids to the same degree, despite histamine being only 35% as effective as carbachol on [3H]InsP accumulation. Histamine and carbachol, at maximal concentrations, were non-additive with respect to both the stimulated incorporation of [3H]inositol and [3H]InsP formation. For carbachol this effect on incorporation was found to occur to a similar extent in PtdInsP and PtdInsP2 as well as PtdIns. The initial effect of carbachol on [3H]inositol incorporation was rapid (maximal by 10 min); however, with prolonged stimulation large secondary declines in PtdInsP and PtdInsP2 labelling were observed, with depletion of the much larger PtdIns pool only evident in the presence of Li+. Lowering buffer [Ca2+] increased the incorporation of [3H]inositol under basal conditions, but did not attenuate the subsequent agonist-stimulated incorporation effect. The large changes in specific radioactivity of the phosphoinositides, and consequently the [3H]InsP products, after carbachol stimulation resulted in the apparent failure of atropine to reverse the [3H]InsP response completely. Labelling muscle slices with [3H]inositol in the presence of carbachol or labelling for longer periods (greater than 6 h) prevented subsequent carbachol-stimulated effects on incorporation without significantly altering the dose-response relationship for carbachol-stimulated [3H]InsP formation and resulted in steady-state labelling conditions confirmed by the ability of atropine to reverse fully the [3H]InsP response to carbachol. This study demonstrates the profound effects of a number of agonists on [3H]inositol incorporation into the phospho- and polyphosphoinositides in BTSM with important consequent changes in the specific radioactivity of these lipids and the resulting [3H]InsP products. In addition, a selective depletion of PtdInsP and PtdInsP2 over PtdIns has been demonstrated with prolonged muscarinic-receptor stimulation.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-1267780, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-13084667, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-164246, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-18462, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-217364, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2417230, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2432219, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2452969, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2725701, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2849446, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2905910, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2906146, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-2981282, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3014119, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3021749, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3028426, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3304132, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3707540, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-3876861, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-4377209, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6157980, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6194786, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6259001, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6320795, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6323632, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6323902, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6330778, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6423773, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-6593735, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-7037762, http://linkedlifedata.com/resource/pubmed/commentcorrection/2556108-7150264
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0264-6021
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
262
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
739-46
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Characterization of agonist-stimulated incorporation of myo-[3H]inositol into inositol phospholipids and [3H]inositol phosphate formation in tracheal smooth muscle.
pubmed:affiliation
Department of Pharmacology and Therapeutics, University of Leicester, U.K.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't